Disseminated intravascular coagulation medical therapy: Difference between revisions
(Created page with " ==Medical therapy== The underlying cause must be treated initially. Anticoagulants are only given when indicated (development of thrombotic renal complications) as patients ...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Template:DIC}} | |||
{{CMG}} | |||
==Overview== | |||
==Medical therapy== | ==Medical therapy== | ||
The underlying cause must be treated initially. Anticoagulants are only given when indicated (development of thrombotic renal complications) as patients with DIC are prone to bleeding. Platelets may be [[Blood transfusion|transfused]] if counts are very low, and [[fresh frozen plasma]] may be administered. | The underlying cause must be treated initially. Anticoagulants are only given when indicated (development of thrombotic renal complications) as patients with DIC are prone to bleeding. Platelets may be [[Blood transfusion|transfused]] if counts are very low, and [[fresh frozen plasma]] may be administered. | ||
| Line 6: | Line 8: | ||
DIC results in lower [[fibrinogen]] (as it has all been converted to fibrin), and this can be tested for in the [[medical laboratory|hospital lab]]. A more specific test is for "fibrin split products" (FSPs) or "[[fibrin degradation products]]" (FDPs) which are produced when fibrin undergoes degradation when blood clots are dissolved by [[fibrinolysis]]. | DIC results in lower [[fibrinogen]] (as it has all been converted to fibrin), and this can be tested for in the [[medical laboratory|hospital lab]]. A more specific test is for "fibrin split products" (FSPs) or "[[fibrin degradation products]]" (FDPs) which are produced when fibrin undergoes degradation when blood clots are dissolved by [[fibrinolysis]]. | ||
In some situations, infusion with [[antithrombin]] may be necessary. A new development is [[drotrecogin alfa]] (Xigris®), a[[recombinant]] activated [[protein C]] product. Activated Protein C (APC) deactivates clotting [[Factor V|factors V]] and [[Factor VIII|VIII]], and the presumed mechanism of action of drotrecogin is the cessation of the intravascular coagulation. Due to its high cost, it is only used strictly on indication in [[intensive care]] patients.<ref>{{cite journal | author = Dhainaut J, Yan S, Joyce D, Pettilä V, Basson B, Brandt J, Sundin D, Levi M | title = Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. | journal = J Thromb Haemost | volume = 2 | issue = 11 |pages = 1924-33 | year = 2004 | id = PMID 15550023}}</ref> | In some situations, infusion with [[antithrombin]] may be necessary. A new development is [[drotrecogin alfa]] (Xigris®), a [[recombinant]] activated [[protein C]] product. Activated Protein C (APC) deactivates clotting [[Factor V|factors V]] and [[Factor VIII|VIII]], and the presumed mechanism of action of drotrecogin is the cessation of the intravascular coagulation. Due to its high cost, it is only used strictly on indication in [[intensive care]] patients.<ref>{{cite journal | author = Dhainaut J, Yan S, Joyce D, Pettilä V, Basson B, Brandt J, Sundin D, Levi M | title = Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. | journal = J Thromb Haemost | volume = 2 | issue = 11 |pages = 1924-33 | year = 2004 | id = PMID 15550023}}</ref> | ||
The prognosis for those with DIC, depending on its cause, is often grim, leading the initials to be known colloquially as "death is coming".<ref>{{cite journal | author = Norman K | title = Alternative treatments for disseminated intravascular coagulation. |journal = Drug News Perspect | volume = 17 | issue = 4 | pages = 243-50 | year = 2004 | id = PMID 15334173}}</ref> | The prognosis for those with DIC, depending on its cause, is often grim, leading the initials to be known colloquially as "death is coming".<ref>{{cite journal | author = Norman K | title = Alternative treatments for disseminated intravascular coagulation. |journal = Drug News Perspect | volume = 17 | issue = 4 | pages = 243-50 | year = 2004 | id = PMID 15334173}}</ref> | ||
| Line 18: | Line 20: | ||
* Transfusion: FFP (fresh frozen plasma), cryoprecipitate and platelets can be used in patients with severe hemorrhage and hemodynamic compromise as long as ‘the accelerated consumption process is under control’. | * Transfusion: FFP (fresh frozen plasma), cryoprecipitate and platelets can be used in patients with severe hemorrhage and hemodynamic compromise as long as ‘the accelerated consumption process is under control’. | ||
*:* The feared ‘adding fuel to the fire’ has never been unequivocally proved. | *:* The feared ‘adding fuel to the fire’ has never been unequivocally proved. | ||
==References== | |||
{{reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
Revision as of 17:45, 28 August 2012
|
Disseminated intravascular coagulation Microchapters |
|
Differentiating Disseminated intravascular coagulation from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Disseminated intravascular coagulation medical therapy On the Web |
|
American Roentgen Ray Society Images of Disseminated intravascular coagulation medical therapy |
|
FDA on Disseminated intravascular coagulation medical therapy |
|
CDC on Disseminated intravascular coagulation medical therapy |
|
Disseminated intravascular coagulation medical therapy in the news |
|
Blogs on Disseminated intravascular coagulation medical therapy |
|
Directions to Hospitals Treating Disseminated intravascular coagulation |
|
Risk calculators and risk factors for Disseminated intravascular coagulation medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical therapy
The underlying cause must be treated initially. Anticoagulants are only given when indicated (development of thrombotic renal complications) as patients with DIC are prone to bleeding. Platelets may be transfused if counts are very low, and fresh frozen plasma may be administered.
DIC results in lower fibrinogen (as it has all been converted to fibrin), and this can be tested for in the hospital lab. A more specific test is for "fibrin split products" (FSPs) or "fibrin degradation products" (FDPs) which are produced when fibrin undergoes degradation when blood clots are dissolved by fibrinolysis.
In some situations, infusion with antithrombin may be necessary. A new development is drotrecogin alfa (Xigris®), a recombinant activated protein C product. Activated Protein C (APC) deactivates clotting factors V and VIII, and the presumed mechanism of action of drotrecogin is the cessation of the intravascular coagulation. Due to its high cost, it is only used strictly on indication in intensive care patients.[1]
The prognosis for those with DIC, depending on its cause, is often grim, leading the initials to be known colloquially as "death is coming".[2]
Essentials of DIC Therapy
- The heterogeneity of DIC has been a major obstacle in the development of controlled prospective trials of therapy.
- The overall goal of therapy should be to reverse the inciting event, and control the major suspected pathophysiologic process in addition to providing overall supportive care.
- As micro and macrovascular thrombi are thought to be major contributors to morbidity and mortality, a great deal of attention has focused on anticoagulation, and even thrombolysis.
- In cases where bleeding is the predominant manifestation, however, inhibition of plasmin may be crucial.
- Transfusion: FFP (fresh frozen plasma), cryoprecipitate and platelets can be used in patients with severe hemorrhage and hemodynamic compromise as long as ‘the accelerated consumption process is under control’.
- The feared ‘adding fuel to the fire’ has never been unequivocally proved.
References
- ↑ Dhainaut J, Yan S, Joyce D, Pettilä V, Basson B, Brandt J, Sundin D, Levi M (2004). "Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation". J Thromb Haemost. 2 (11): 1924–33. PMID 15550023.
- ↑ Norman K (2004). "Alternative treatments for disseminated intravascular coagulation". Drug News Perspect. 17 (4): 243–50. PMID 15334173.